Additional Relevant Details MGD007 is a humanized, Dual-Affinity Re-Targeting, or DART, molecule that recognizes both the glycoprotein A33 antigen, or gpA33, and CD3 and was MacroGenics' first clinical DART molecule designed to target solid tumors.  

This study is designed to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) of MGD007 administered on either weekly or every three week schedules of administration among patients with metastatic colorectal carcinoma. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of MGD007 will also be assessed.